-
Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled TrialK Kanenawa, K Yamaji, H Tashiro et al. -
A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trialWJ Jang, JB Lee, YB Song et al.
-
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert PanelD Capodanno, MC Morice, DJ Angiolillo et al.
-
Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapyvan Rein N, Heide-Jørgensen U, Lijfering WM et al.
-
Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS RegistryJoyce LC, Baber U, Mehran R et al.
-
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS TrialSS Anand, JW Eikelboom, COMPASS Trial Investigators.
-
The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall shortCosta F, Valgimigli M.
-
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stentsMauri L, Kereiakes DJ, DAPT Study Investigators.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
